Roche Invests In Halozyme Biologics Delivery Platform
This article was originally published in The Pink Sheet Daily
Executive Summary
Halozyme’s Enhanze technology could be used with virtually all biologics to improve drug delivery, the company says.
You may also be interested in...
Halozyme's 2017 Includes PEGPH20 Milestones, New Partnership
Halozyme CEO Helen Torley spoke with Scrip about execution of the company's strategy – reworked after her arrival in 2014 – to focus on oncology drug development and partnerships using its Enhanze platform.
Subcutaneous Partnerships Are Stepping Stones: Halozyme Touts Its Insulin Product
Despite multiple partnerships around a technology platform that can ease administration of existing drugs, Halozyme says its future prospects revolve more around a significant opportunity in insulin-pump products.
Subcutaneous Herceptin Meets Goals In Phase III Trial
New subcutaneous formulation of Roche's breast cancer biologic Herceptin is comparable to intravenous version, prompting the companies to file for approval in Europe in 2012. Yet, U.S. filing could take longer.